Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats

Pharmacology Biochemistry and Behavior

Volumn 97, Issue 1, 2010, Pages 163-169

  Evers, S S ^a   Calcagnoli, F ^a   van Dijk, G ^a   Scheurink, A J W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Body weight; Feeding behavior; Hypothermia; Locomotor activity; Meal size; Olanzapine; Rat

Indexed keywords

OLANZAPINE;

ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; CATHETER; CIRCADIAN RHYTHM; DRUG EFFECT; FEEDING BEHAVIOR; FEEDING DISORDER; FEMALE; FLUID INTAKE; FOOD INTAKE; HYPOTHERMIA; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ANIMALS; BENZODIAZEPINES; DRUG ADMINISTRATION SCHEDULE; FEEDING BEHAVIOR; FEMALE; HYPOTHERMIA; MOTOR ACTIVITY; RATS; RATS, WISTAR; SUCROSE; WEIGHT GAIN;

RATTUS; RATTUS NORVEGICUS;

EID: 77957752574     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.05.029     Document Type: Article

References (47)

1. Ahnaou A., Megens A.A.H.P., Drinkenburg W.H.I.M. The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats. Neuropsychobiology 2003, 48:47-54.
2. Aichhorn W., Whitworth A.B., Weiss E.M., Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?. Drug Saf 2006, 29:587.
3. Ananth J., Venkatesh R., Burgoyne K., Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002, 71:244-254.
4. Angelucci F., Aloe L., Iannitelli A., Gruber S.H., Mathe A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropsychopharmacol 2005, 15:311-317.
5. Baptista T., Kin N.M., Beaulieu S., de Baptista E.A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002, 35:205-219.
6. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14:87-96.
7. Bymaster F.P., Hemrick-Luecke S.K., Perry K.W., Fuller R.W. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl) 1996, 124:87-94.
8. Bymaster F.P., Nelson D.L., DeLapp N.W., Falcone J.F., Eckols K., Truex L.L., et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 1999, 37:107-122.
9. Bymaster F.P., Falcone J.F., Bauzon D., Kennedy J.S., Schenck K., DeLapp N.W., et al. Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine. Eur J Pharmacol 2001, 430:341-349.
10. Caballero E. Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy. CNS Spectr 2003, 8:19-22.
11. Callaghan J.T., Cerimele B.J., Kassahun K.J., Nyhart E.H., Hoyes-Beehler P.J., Kondraske G.V. Olanzapine: interaction study with imipramine. J Clin Pharmacol 1997, 37:971-978.
12. Choi S., DiSilvio B., Unangst J., Fernstrom J.D. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci 2007, 81:1024-1030.
13. Cohen J.A., Perel J.M. Adolescent weight loss during treatment with olanzapine. J Child Adolesc Psychopharmacol 2004, 14:617-620.
14. Cooper G.D., Pickavance L.C., Wilding J.P., Halford J.C., Goudie A.J. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 2005, 181:80-89.
15. Cooper G.D., Pickavance L.C., Wilding J.P., Harrold J.A., Halford J.C., Goudie A.J. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 2007, 21:405-413.
16. Davoodi N., Kalinichev M., Korneev S.A., Clifton P.G. Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology (Berl) 2009, 203:693-702.
17. Eder U., Mangweth B., Ebenbichler C., Weiss E., Hofer A., Hummer M., et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001, 158:1719-1722.
18. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988, 45:71-76.
19. Gothelf D., Falk B., Singer P., Kairi M., Phillip M., Zigel L., et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002, 159:1055-1057.
20. Hajduch E., Rencurel F., Balendran A., Batty I.H., Downes C.P., Hundal H.S. Serotonin (5-hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. J Biol Chem 1999, 274:13563-13568.
21. Hillebrand J.J., van Elburg A.A., Kas M.J., van E.H., Adan R.A. Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?. Biol Psychiatry 2005, 58:651-657.
22. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003, 305:625-631.
23. Lacroix L.P., Hows M.E., Shah A.J., Hagan J.J., Heidbreder C.A. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 2003, 28:839-849.
24. Lee M.D., Clifton P.G. Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol. Pharmacol Biochem Behav 2002, 71:147-154.
25. Li X.M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 1998, 136:153-161.
26. Meerlo P., De Boer S.F., Koolhaas J.M., Daan S., Van den Hoofdakker R.H. Changes in daily rhythms of body temperature and activity after a single social defeat in rats. Physiol Behav 1996, 59:735-739.
27. Molina-Hernandez M., Tellez-Alcantara N.P., Olivera-Lopez J.I., Jaramillo M.T. Olanzapine plus 17-beta estradiol produce antidepressant-like actions in rats forced to swim. Pharmacol Biochem Behav 2009, 93:491-497.
28. Monda M., Viggiano A., Viggiano A., Mondola R., Viggiano E., Messina G., et al. Olanzapine blocks the sympathetic and hyperthermic reactions due to cerebral injection of orexin A. Peptides 2008, 29:120-126.
29. Naiker D.V., Catts S.V., Catts V.S., Bedi K.S., Bryan-Lluka L.J. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol 2006, 540:87-90.
30. Oerther S., Ahlenius S. Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat. J Pharmacol Exp Ther 2000, 292:731-736.
31. Pouzet B., Mow T., Kreilgaard M., Velschow S. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 2003, 75:133-140.
32. Putzhammer A., Perfahl M., Pfeiff L., Hajak G. Gait disturbances in patients with schizophrenia and adaptation to treadmill walking. Psychiatry Clin Neurosci 2005, 59:303-310.
33. Richtand N.M., Kelsoe J.R., Segal D., Kuczenski R. Regional quantification of D1, D2, and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay. Mol Brain Res 1995, 33:97-103.
34. Robertson G.S., Fibiger H.C. Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology 1996, 14:105-110.
35. Roerig J.L., Mitchell J.E., de Z.M., Crosby R.D., Gosnell B.A., Steffen K.J., et al. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. J Clin Psychopharmacol 2005, 25:413-418.
36. Rollema H., Lu Y., Schmidt A.W., Sprouse J.S., Zorn S.H. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000, 48:229-237.
37. Sawchenko P.E., Swanson L.W., Steinbusch H.W.M., Verhofstad A.A.J. The distribution and cells of origin of serotonergic inputs to the paraventricular and supraoptic nuclei of the rat. Brain Res 1983, 277:355-360.
38. Stauffer V.L., Lipkovich I., Hoffmann V.P., Heinloth A.N., McGregor H.S., Kinon B.J. Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. BMC Psychiatry 2009, 9:12.
39. Stefanidis A., Verty A.N., Allen A.M., Owens N.C., Cowley M.A., Oldfield B.J. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity 2009, 17:16-24. (Silver. Spring).
40. Tavares A., Handy D.E., Bogdanova N.N., Rosene D.L., Gavras H. Localization of {alpha}2A- and {alpha}2B-adrenergic receptor subtypes in brain. Hypertension 1996, 27:449-455.
41. van der Zwaal E.M., Luijendijk M.C., Adan R.A., la Fleur S.E. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol 2008, 585:130-136.
42. Victoriano M., Hermier D., Even P.C., Fromentin G., Huneau J.F., Tome D., et al. Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats. Psychopharmacology (Berl) 2009, 206:167-176.
43. Wielinga P.Y., Wachters-Hagedoorn R.E., Bouter B., van Dijk T.H., Stellaard F., Nieuwenhuizen A.G., et al. Hydroxycitric acid delays intestinal glucose absorption in rats. Am J Physiol Gastrointest Liver Physiol 2005, 288:G1144-G1149.
44. Yang T.T., Chang C.K., Tsao C.W., Hsu Y.M., Hsu C.T., Cheng J.T. Activation of muscarinic M-3 receptor may decrease glucose uptake and lipolysis in adipose tissue of rats. Neurosci Lett 2009, 451:57-59.
45. Yoshimatsu H. Hypothalamic neuronal histamine regulates body weight through the modulation of diurnal feeding rhythm. Nutrition 2008, 24:827-831.
46. Yu W.Z., Silva R.M., Sclafani A., Delamater A.R., Bodnar R.J. Pharmacology of flavor preference conditioning in sham-feeding rats: effects of dopamine receptor antagonists. Pharmacol Biochem Behav 2000, 65:635-647.
47. Zubieta J.K., Frey K.A. Autoradiographic mapping of M3 muscarinic receptors in the rat brain. J Pharmacol Exp Ther 1993, 264:415-422.